COMPARISONS OF THE ORIGINAL, EXPANDED, AND MODIFIED FUCHS EXACERBATION DEFINITIONS IN ASSESSING ATALUREN-ASSOCIATED EXACERBATION BENEFITS IN CYSTIC FIBROSIS PATIENTS WITH A CFTR NONSENSE MUTATION NOT RECEIVING CHRONIC INHALED AMINOGLYCOSIDE THERAPY

McIntosh J.; VanDevanter D. R.

首页> 外文期刊>Pediatric Pulmonology >COMPARISONS OF THE ORIGINAL, EXPANDED, AND MODIFIED FUCHS EXACERBATION DEFINITIONS IN ASSESSING ATALUREN-ASSOCIATED EXACERBATION BENEFITS IN CYSTIC FIBROSIS PATIENTS WITH A CFTR NONSENSE MUTATION NOT RECEIVING CHRONIC INHALED AMINOGLYCOSIDE THERAPY

【24h】

COMPARISONS OF THE ORIGINAL, EXPANDED, AND MODIFIED FUCHS EXACERBATION DEFINITIONS IN ASSESSING ATALUREN-ASSOCIATED EXACERBATION BENEFITS IN CYSTIC FIBROSIS PATIENTS WITH A CFTR NONSENSE MUTATION NOT RECEIVING CHRONIC INHALED AMINOGLYCOSIDE THERAPY

机译：在CFTR无意义突变的囊性纤维化患者评估不接受慢性吸入性氨基糖苷治疗的囊性纤维化患者中，原发性，扩大性和改良型FUCHS加重定义的比较

获取原文

获取原文并翻译 | 示例

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Pediatric Pulmonology》 |2016年第51期|共1页
作者
McIntosh J.; VanDevanter D. R.;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类儿科学;
关键词

相似文献

外文文献
中文文献
专利

1. COMPARISONS OF THE ORIGINAL, EXPANDED, AND MODIFIED FUCHS EXACERBATION DEFINITIONS IN ASSESSING ATALUREN-ASSOCIATED EXACERBATION BENEFITS IN CYSTIC FIBROSIS PATIENTS WITH A CFTR NONSENSE MUTATION NOT RECEIVING CHRONIC INHALED AMINOGLYCOSIDE THERAPY [J] . McIntosh J., VanDevanter D. R. Pediatric Pulmonology . 2016,第Suppla51期

机译：在CFTR无意义突变的囊性纤维化患者评估不接受慢性吸入性氨基糖苷治疗的囊性纤维化患者中，原发性，扩大性和改良型FUCHS加重定义的比较
2. CLINICAL BENEFITS OF ATALUREN IN CYSTIC FIBROSIS PATIENTS WITH A CFTR NONSENSE MUTATION NOT RECEIVING CHRONIC INHALED TOBRAMYCIN [J] . De Boeck C., Heijerman H., Davies J. C., Pediatric Pulmonology . 2016,第Suppla51期

机译：CFTA无意义突变的囊性纤维化患者中他鲁仑的临床益处不接受慢性吸入妥布霉素
3. CLINICAL BENEFITS OF ATALUREN IN CYSTIC FIBROSIS PATIENTS WITH A CFTR NONSENSE MUTATION NOT RECEIVING CHRONIC INHALED TOBRAMYCIN [J] . De Boeck C., Heijerman H., Davies J. C., Pediatric Pulmonology . 2016,第Suppla45期

机译：Ataluren在囊性纤维化患者中患有CFTR无意义突变的临床益处，未接受慢性吸入伯霉素
4. Assessing time to pulmonary function benefit following antibiotic treatment of acute cystic fibrosis exacerbations [O] . Donald R VanDevanter, Mary A ORiordan, Jeffrey L Blumer, 2010

机译：抗生素治疗急性囊性纤维化加重后评估肺功能获益时间
5. WS13.1 Ataluren significantly reduces exacerbations in nonsense mutation cystic fibrosis patients not receiving tobramycin [O] . K. De Boeck, H.G.M. Heijerman, J.C. Davies, 2016

机译：WS13.1 Ataluren显着降低了未接受伯霉素的非突变突变囊性纤维化患者的恶化

COMPARISONS OF THE ORIGINAL, EXPANDED, AND MODIFIED FUCHS EXACERBATION DEFINITIONS IN ASSESSING ATALUREN-ASSOCIATED EXACERBATION BENEFITS IN CYSTIC FIBROSIS PATIENTS WITH A CFTR NONSENSE MUTATION NOT RECEIVING CHRONIC INHALED AMINOGLYCOSIDE THERAPY

著录项

相似文献

相关主题

期刊订阅